---
figid: PMC9006990__fmolb-09-870395-g002
figtitle: Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC9006990
filename: fmolb-09-870395-g002.jpg
figlink: /pmc/articles/PMC9006990/figure/F2/
number: F2
caption: 'EGFR pathway. In malignant cells, EGF combine to EGFR and activate the EGFR
  pathway which initiates a downstream signaling cascade through the RAS/RAF/MAPK
  and the PI3K/AKT/mTOR axes and then promotes cell proliferation. Cetuximab and panitumumab
  are anti-EGFR mAbs, which by competitive binding to the extracellular domain of
  EGFR lead to the internalization, degradation of the receptor, and inhibition of
  the EGFR signal transduction pathway and also through the antibody-dependent cytotoxic
  effect inhibit the proliferation of tumor cells and induce apoptosis, so as to achieve
  the effect of tumor control. Abbreviations: AKT, AKT8 virus oncogene cellular homolog;
  EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase;
  MEK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; PI3K,
  phosphatidyilinositol 3-kinase; PTEN, phosphatase and tensin homolog; RAF, v-Raf
  murine sarcoma viral oncogene homolog; and RAS, rat sarcoma viral oncogene homolog.'
papertitle: The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy.
reftext: Meiqin Yuan, et al. Front Mol Biosci. 2022;9:870395.
year: '2022'
doi: 10.3389/fmolb.2022.870395
journal_title: Frontiers in Molecular Biosciences
journal_nlm_ta: Front Mol Biosci
publisher_name: Frontiers Media S.A.
keywords: mCRC | maintenance therapy | EGFR | monoclonal antibody | panitumumab |
  cetuximab
automl_pathway: 0.9247934
figid_alias: PMC9006990__F2
figtype: Figure
redirect_from: /figures/PMC9006990__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9006990__fmolb-09-870395-g002.html
  '@type': Dataset
  description: 'EGFR pathway. In malignant cells, EGF combine to EGFR and activate
    the EGFR pathway which initiates a downstream signaling cascade through the RAS/RAF/MAPK
    and the PI3K/AKT/mTOR axes and then promotes cell proliferation. Cetuximab and
    panitumumab are anti-EGFR mAbs, which by competitive binding to the extracellular
    domain of EGFR lead to the internalization, degradation of the receptor, and inhibition
    of the EGFR signal transduction pathway and also through the antibody-dependent
    cytotoxic effect inhibit the proliferation of tumor cells and induce apoptosis,
    so as to achieve the effect of tumor control. Abbreviations: AKT, AKT8 virus oncogene
    cellular homolog; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated
    kinase; MEK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin;
    PI3K, phosphatidyilinositol 3-kinase; PTEN, phosphatase and tensin homolog; RAF,
    v-Raf murine sarcoma viral oncogene homolog; and RAS, rat sarcoma viral oncogene
    homolog.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Raf
  - Dsor1
  - Mtk
  - Egfr
  - ras
  - Ras64B
  - Ras85D
  - Erk7
  - rl
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Mtor
  - Tor
  - Pten
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EGF
  - EGFR
  - KRAS
  - HRAS
  - NRAS
  - EPHB2
  - MAPK1
  - MAPK3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - PTEN
---
